Virtus Biotech ETF
- ETF
- Ticker BBP
- NYSE
Performance, volatility and drawdowns of Virtus Biotech ETF since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $26,731. Global equities (VT): $29,042.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −44.3% in 05/2022, measured from the peak in 02/2021. It took 37 months to get back to the old peak.
Factor profile
Monthly returns 12/2016 to 09/2026, measured against USA. The factors explain 51% of the variation.
- Market
- 0.58
- Size
- 0.78
- Value
- −0.42
- Profitability
- −0.46
- Low investment
- 0.17
- Momentum
- −0.11
How to read this: BBP moves less than the stock market (USA): when the market rises by 1%, the ETF rises by 0.58% on average. The ETF leans towards small companies, highly valued growth stocks and less profitable companies.
A value of 1 for the market means: when the market rises by 1%, the ETF rises by 1% on average. The other values show the lean towards small, cheaply valued, profitable, conservatively investing and recently strong stocks; bold where it is clear. Calculated with the Fama and French factors and momentum.
Annual returns
Best year 2025 at +33.2%, weakest 2018 at −14.0%. 7 of 9 full years were positive. * partial year.
Similar ETFs
Frequently asked questions
How has BBP performed since 11/2016?
$10,000 grew to $26,731 by 20 Nov 2026, which is +10.3% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is BBP?
Volatility was 21.6% per year, measured on monthly returns. The largest decline from a peak was −44.3%, with the low in 05/2022.
How does BBP compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, BBP returned +10.3% at 21.6%. The correlation of monthly returns was 0.57; 1 would mean they moved in lockstep.
What does BBP hold?
BBP holds 67 positions. The largest are CRINETICS PHARMACEUTICALS INC COM, KINIKSA PHARMACEUTICALS INTERNATIONAL PLC ORD SHS CL A and VERASTEM INC COM NEW; the 10 largest together make up 19.6% of the fund (holdings as of 31 Jul 2026, according to the fund's filing with the SEC).
Which currency are the figures in?
In US dollars, the currency of the US listing.